Our results demonstrate that Lv-PD1-γδ T cells can generate functional anti-PD-1 antibodies to block the PD-1/PD-L1 inhibitory pathway, resulting in enhanced cytotoxicity and improved therapeutic efficacy in ovarian cancer by secreting high levels of IFN-γ, TNF-α, and granzyme A/B. The gene discussed is PDCD1; the disease is ovarian carcinoma.